Cholangiocarcinoma PDX Models
Identifying robust preclinical models for cholangiocarcinoma is essential for the development of targeted therapies. Patient-derived xenograft (PDX) models provide a predictive preclinical model with true representation of the human heterogeneity. The Crown Bioscience cholangiocarcinoma PDX collection consists of several models which provide an accurate approach to predicting an agents efficacy prior to entering the clinic. More
PDX offer the most translational preclinical model for efficacy screening in cancer drug development. Derived directly from patient tumors and never adapted to grow in vitro, PDX models reflect the heterogeneity and diversity of the human patient population. PDX give you an accurate, predictive model of how your treatment will perform, well before entering into expensive clinical trials. Crown Bioscience’s HuPrime® PDX models are well characterized for pathology, growth characteristics, and are also genetically/genomically annotated for gene expression, gene copy number, mutations, and fusions.